MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats

Radiology

Volumn 243, Issue 1, 2007, Pages 105-111

  Fournier, Laure S ^a,b   Novikov, Viktor ^a   Lucidi, Vincenzo ^a   Fu, Yanjun ^a   Miller, Theodore ^a   Floyd, Eugenia ^a   Shames, David M ^a   Brasch, Robert C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CONTRAST MEDIUM; CYCLOOXYGENASE 2 INHIBITOR; GADOMER 17; SHL 643A; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER CELL CULTURE; CANCER MODEL; CONTRAST ENHANCEMENT; DRUG EFFECT; DRUG MONITORING; DRUG PENETRATION; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MACROMOLECULE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE RAT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; TREATMENT DURATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; PYRAZOLES; RATS; RATS, NUDE; SULFONAMIDES;

EID: 34147221918     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2431050658     Document Type: Article

References (38)

1. Avastin (bevacizumab), U.S. Food and Drug Administration Web site. http://www.fda.gov/cder/drug/infopage/Avastin/. Accessed August 6, 2004.
2. Clement O, Pradel C, Siauve N, et al. Assessing perfusion and capillary permeability changes induced by a VEGF inhibitor in human tumor xenografts using macromolecular MR imaging contrast media. Acad Radiol 2002;9(suppl 2):S328-S329.
3. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998;171:941-949.
4. Daldrup-Link HE, Rydland J, Helbich TH, et al. Quantification of breast tumor microvascular permeability with feruglose-enhanced MR imaging: initial phase II multicenter trial. Radiology 2003;229:885-892.
5. Daldrup-Link HE, Shames DM, Wendland M, et al. Comparison of Gadomer-17 and gadopentetate dimeglumine for differentiation of benign from malignant breast tumors with MR imaging. Acad Radiol 2000;7:934-944.
6. de Lussanet QG, Langereis S, Beets-Tan RG, et al. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 2005;235:65-72.
7. Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002;15:233-240.
8. Petrovsky A, Weissleder R, Hu-Lowe D, Shalinsky D, Bogdanov A. Non-invasive MR imaging of anti-angiogenic effects induced by a VEGF-RTKI in a human xenograft model [abstr]. In: Proceedings of the 10th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2002; 317.
9. Phann CD, Roberts TP, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;16:225-230.
10. Roberts T, Preda A, Turetschek K, et al. Permeability of B22956/1, a novel protein-binding contrast agent, resolves anti-angiogenic therapy in human breast cancer model [abstr]. In: Proceedings of the 10th Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2002; 319.
11. Schwickert HC, Stiskal M, Roberts TP, et al. Contrast-enhanced MRI assessment of tumor capillary permeability: the effect of pre-irradiation on the tumor delivery of chemotherapy. Radiology 1996;198:893-898.
12. Gossmann A, Helhich TH, Mesiano S, et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000;183:956-963.
13. Turetschek K, Preda A, Floyd E, et al. MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 2002;9(suppl 2):S519-S520.
14. Wiart M, Fournier LS, Novikov VY, et al. Magnetic resonance imaging detects early changes in microvascular permeability in xenograft tumors after treatment with the matrix metalloprotease inhibitor prinomastat. Technol Cancer Res Treat 2004;3:377-382.
15. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114.
16. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
17. Kundu N, Falton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002;62:2343-2346.
18. Lin XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996;56:5125-5127.
19. van Vaals JJ, Brammer ME, Dixon WT, et al. "Keyhole" method for accelerating imaging of contrast agent uptake. J Magn Reson Imaging 1993;3:671-675.
20. Roberts TP, Roberts HC, Brasch RC. Optimizing imaging techniques to reduce errors in microvascular quantitation with macromolecular MR contrast agents. Acad Radiol 1998;5(suppl 1):S133-S136.
21. Shames DM, Kuwatsura R, Vexler V, Muhler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 1993;29:616-622.
22. Cobelli C, Foster D, Toffolo G. Tracer kinetics in biomedical research: from data to model. New York, NY: Kluwer Academic/Plenum Publishers, 2000.
23. Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flelleh C, Burton J. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, colecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 2001;7:3178-3185.
24. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995;36:169-180.
25. NCI-sponsored trials of celecoxib for cancer prevention. National Cancer Institute Web site. http://newscenter.cancer.gov/pressreleases/celecoxibupdate. html. Accessed April 18, 2004.
26. Myers C, Koki A, Pamuken R, Wechter W, Padley RJ. Proapoptotic anti-inflammatory drugs. Urology 2001;57:73-76.
27. Masferrer JL, Leaby KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311.
28. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998;97:99-107.
29. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
30. Nassmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
31. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
32. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-1381.
33. Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identificalion and characterization of the blood vessels of solid tumors that are leaky to circulating macromulecules. Am J Pathol 1988;133:95-109.
34. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305.
35. Hashizume H, Balok P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-1380.
36. Brasch RC, Li KC, Husband JE, et al. In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 2000;7:812-823.
37. Henser LS, Miller FN. Differential macromolecular leakage from the vasculature of tumors. Cancer 1986;57:461-464.
38. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987;6:559-593.